Shares of Orthopediatrics Corp (NASDAQ:KIDS) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $35.56 and last traded at $35.46, with a volume of 806 shares trading hands. The stock had previously closed at $34.20.

A number of analysts have recently issued reports on the company. ValuEngine upgraded Orthopediatrics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. BidaskClub cut Orthopediatrics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 18th. Zacks Investment Research cut Orthopediatrics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 14th. William Blair reiterated an “outperform” rating on shares of Orthopediatrics in a research report on Wednesday, June 27th. Finally, Piper Jaffray Companies upped their price target on Orthopediatrics from $24.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, July 5th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. Orthopediatrics has a consensus rating of “Buy” and a consensus price target of $25.67.

The company has a current ratio of 5.98, a quick ratio of 3.61 and a debt-to-equity ratio of 0.60.

Orthopediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.07). Orthopediatrics had a negative net margin of 61.99% and a negative return on equity of 192.23%. The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.27 million. The company’s revenue for the quarter was up 28.0% compared to the same quarter last year. analysts expect that Orthopediatrics Corp will post -0.96 EPS for the current fiscal year.

In other Orthopediatrics news, Director Kevin Unger sold 1,000 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $33.22, for a total value of $33,220.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, General Counsel Daniel J. Gerritzen sold 9,525 shares of the stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $33.73, for a total value of $321,278.25. The disclosure for this sale can be found here. Corporate insiders own 46.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Novo Holdings A S grew its holdings in shares of Orthopediatrics by 4.6% during the second quarter. Novo Holdings A S now owns 653,349 shares of the company’s stock worth $17,405,000 after purchasing an additional 28,758 shares during the last quarter. Wasatch Advisors Inc. grew its holdings in shares of Orthopediatrics by 70.1% during the second quarter. Wasatch Advisors Inc. now owns 401,049 shares of the company’s stock worth $10,684,000 after purchasing an additional 165,234 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Orthopediatrics by 74.9% during the second quarter. BlackRock Inc. now owns 341,196 shares of the company’s stock worth $9,090,000 after purchasing an additional 146,115 shares during the last quarter. Waddell & Reed Financial Inc. grew its holdings in shares of Orthopediatrics by 2.5% during the second quarter. Waddell & Reed Financial Inc. now owns 228,500 shares of the company’s stock worth $6,087,000 after purchasing an additional 5,649 shares during the last quarter. Finally, Cortina Asset Management LLC grew its holdings in shares of Orthopediatrics by 54.0% during the first quarter. Cortina Asset Management LLC now owns 199,269 shares of the company’s stock worth $3,001,000 after purchasing an additional 69,884 shares during the last quarter. Institutional investors own 40.16% of the company’s stock.

Orthopediatrics Company Profile (NASDAQ:KIDS)

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, locking cannulated blades, locking proximal femurs, spica tables, response spine systems, and pediguards; bandloc, a sub-laminar banding system; and sports medicine and other products, such as anterior cruciate ligament and medial patellofemoral ligament systems.

Featured Article: Determine Your Level of Risk Tolerance

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.